JP5543956B2 - 癌の処置のための方法および組成物 - Google Patents

癌の処置のための方法および組成物 Download PDF

Info

Publication number
JP5543956B2
JP5543956B2 JP2011501983A JP2011501983A JP5543956B2 JP 5543956 B2 JP5543956 B2 JP 5543956B2 JP 2011501983 A JP2011501983 A JP 2011501983A JP 2011501983 A JP2011501983 A JP 2011501983A JP 5543956 B2 JP5543956 B2 JP 5543956B2
Authority
JP
Japan
Prior art keywords
cisplatin
treatment
cancer
arsenic
sodium meta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011501983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515481A5 (https=
JP2011515481A (ja
Inventor
アンジェリカ バーガー，
ハンス ヘンドリクス，
ベルナルダス ラデマーカー，
Original Assignee
コミノックス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コミノックス・インコーポレイテッド filed Critical コミノックス・インコーポレイテッド
Publication of JP2011515481A publication Critical patent/JP2011515481A/ja
Publication of JP2011515481A5 publication Critical patent/JP2011515481A5/ja
Application granted granted Critical
Publication of JP5543956B2 publication Critical patent/JP5543956B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011501983A 2008-03-27 2009-03-24 癌の処置のための方法および組成物 Expired - Fee Related JP5543956B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3998708P 2008-03-27 2008-03-27
US61/039,987 2008-03-27
US12/408,864 2009-03-23
US12/408,864 US20090246291A1 (en) 2008-03-27 2009-03-23 Method and compositions for treatment of cancer
PCT/US2009/038104 WO2009120697A2 (en) 2008-03-27 2009-03-24 Method and compositions for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014046212A Division JP2014101387A (ja) 2008-03-27 2014-03-10 癌の処置のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2011515481A JP2011515481A (ja) 2011-05-19
JP2011515481A5 JP2011515481A5 (https=) 2012-04-05
JP5543956B2 true JP5543956B2 (ja) 2014-07-09

Family

ID=41114644

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011501983A Expired - Fee Related JP5543956B2 (ja) 2008-03-27 2009-03-24 癌の処置のための方法および組成物
JP2014046212A Withdrawn JP2014101387A (ja) 2008-03-27 2014-03-10 癌の処置のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014046212A Withdrawn JP2014101387A (ja) 2008-03-27 2014-03-10 癌の処置のための方法および組成物

Country Status (20)

Country Link
US (2) US20090246291A1 (https=)
EP (1) EP2268292B1 (https=)
JP (2) JP5543956B2 (https=)
KR (1) KR101634138B1 (https=)
CN (2) CN104997808A (https=)
AU (1) AU2009228378B2 (https=)
BR (1) BRPI0909164A2 (https=)
CA (1) CA2719766C (https=)
CY (1) CY1120536T1 (https=)
DK (1) DK2268292T3 (https=)
ES (1) ES2656762T3 (https=)
HU (1) HUE036609T2 (https=)
LT (1) LT2268292T (https=)
MX (1) MX2010010621A (https=)
PL (1) PL2268292T3 (https=)
PT (1) PT2268292T (https=)
RU (1) RU2508116C2 (https=)
SI (1) SI2268292T1 (https=)
WO (1) WO2009120697A2 (https=)
ZA (1) ZA201006988B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504587A (ja) * 2009-09-10 2013-02-07 コミノックス・インコーポレイテッド 癌幹細胞を標的とした薬剤耐性癌治療法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8795738B2 (en) * 2009-11-12 2014-08-05 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CN103153303A (zh) * 2010-07-18 2013-06-12 尼基制药公司 使用钌络合物的联合疗法
ES2718637T3 (es) * 2010-08-24 2019-07-03 Gtx Inc Compuestos para el tratamiento del cáncer
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
CN103826645A (zh) * 2011-05-12 2014-05-28 得克萨斯系统大学评议会 砷在癌症治疗保护中的用途
US8834938B2 (en) 2011-05-18 2014-09-16 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
KR101309844B1 (ko) 2013-03-15 2013-09-23 박상채 항암 활성 증진용 한약재 및 이의 제조방법
WO2014152330A1 (en) * 2013-03-15 2014-09-25 Stc.Unm Arsenic-based treatment of cancers and inflammatory disorders
MX372671B (es) * 2013-07-19 2020-04-23 Onyx Therapeutics Inc Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
ES2964979T3 (es) 2016-12-01 2024-04-10 Eupharma Pty Ltd Composiciones de arsénico
AU2019239671B2 (en) 2018-03-22 2025-02-27 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture
CN116236505A (zh) * 2023-03-15 2023-06-09 上海市第四人民医院 三氧化二砷在制备肺神经内分泌癌治疗药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519366A (ja) * 1997-10-15 2001-10-23 ポーラクス バイオファーマシュティカルズ，インコーポレーテッド ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法
IL136051A0 (en) * 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
EP1496918B1 (en) * 2002-04-10 2023-02-08 Komipharm International Co., Ltd. Use of sodium meta-arsenite for the treatment of tumours
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8097237B2 (en) * 2005-08-23 2012-01-17 Stc.Unm Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
US7867492B2 (en) * 2007-10-12 2011-01-11 The John Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504587A (ja) * 2009-09-10 2013-02-07 コミノックス・インコーポレイテッド 癌幹細胞を標的とした薬剤耐性癌治療法

Also Published As

Publication number Publication date
HUE036609T2 (hu) 2018-07-30
AU2009228378A1 (en) 2009-10-01
WO2009120697A3 (en) 2010-02-18
US20090246291A1 (en) 2009-10-01
MX2010010621A (es) 2011-04-05
ES2656762T3 (es) 2018-02-28
WO2009120697A2 (en) 2009-10-01
CN104997808A (zh) 2015-10-28
EP2268292A2 (en) 2011-01-05
CY1120536T1 (el) 2019-07-10
CA2719766C (en) 2017-10-31
SI2268292T1 (en) 2018-03-30
CA2719766A1 (en) 2009-10-01
KR20110009664A (ko) 2011-01-28
EP2268292A4 (en) 2011-05-11
PL2268292T3 (pl) 2018-06-29
LT2268292T (lt) 2018-03-26
KR101634138B1 (ko) 2016-06-28
AU2009228378B2 (en) 2014-07-17
US20180055812A1 (en) 2018-03-01
RU2010143893A (ru) 2012-05-10
RU2508116C2 (ru) 2014-02-27
WO2009120697A4 (en) 2010-04-15
CN102046187A (zh) 2011-05-04
PT2268292T (pt) 2018-02-19
DK2268292T3 (en) 2018-03-12
JP2011515481A (ja) 2011-05-19
ZA201006988B (en) 2012-05-30
JP2014101387A (ja) 2014-06-05
EP2268292B1 (en) 2017-12-27
BRPI0909164A2 (pt) 2016-06-21

Similar Documents

Publication Publication Date Title
JP5543956B2 (ja) 癌の処置のための方法および組成物
CN102105152B (zh) 包含cdks抑制剂和抗肿瘤剂的治疗组合
EP2435041B1 (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
JP2019508433A (ja) Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法
EP2049121B1 (en) Compositions for promoting activity of anti-cancer therapies
JP2009536956A (ja) 抗癌治療法
TW201509413A (zh) 含有亞鐵胺基酸螯合物之組合物用於製造抗癌症之醫藥品的用途
WO2015172712A1 (zh) 维生素c与抗肿瘤药物协同作用的注射用药物组合物
US9937261B2 (en) Combination therapy comprising a liposomal prodrug of mitomycin C and radiotherapy
JP2014144979A (ja) 治療におけるアポトーシスを増加させるための有糸分裂の阻害剤
Jing et al. Trifluoperazine synergistically potentiates bortezomib-induced anti-cancer effect in multiple myeloma via inhibiting P38 MAPK/NUPR1
JP2021063014A (ja) 白血病治療薬
CN101167741B (zh) 莱菔硫烷和铂类药的抗癌联合制剂
EP3565547B1 (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
WO2020254299A1 (en) Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
US6593303B1 (en) Anti-tumor synergetic composition
HK1152250B (en) Method and compositions for treatment of cancer
HK1152250A (en) Method and compositions for treatment of cancer
KR20060036058A (ko) 결장직장암의 치료를 위한 혈관 손상 활성을 갖는 5ｆｕ,ｃｐｔ-11 또는 5-ｆｕ 및 ｃｐｔ-11과 함께 ｚｄ6126을포함하는 조성물
HK40092504A (zh) 治疗癌症的bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物
HK40060452A (en) COMBINED USE OF A-NOR-5α ANDROSTANE COMPOUND DRUG AND ANTICANCER DRUG
EA040162B1 (ru) Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140310

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140324

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140509

R150 Certificate of patent or registration of utility model

Ref document number: 5543956

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees